


UK & Europe:

Life Sciences & Healthcare
Venture Financing
Report FY 2025

A photograph of two female scientists in a laboratory setting. They are wearing white lab coats and are looking intently at a computer monitor. The background shows various pieces of laboratory equipment, including a microscope and a pipette. The image is overlaid with a white text box on the left side and a purple and blue decorative border on the right and bottom edges.

We work with our clients in life sciences and healthcare to create bespoke lending and global treasury solutions at every stage of growth that advance healthcare and improve lives everywhere.

Executive Summary

UK & Europe Life Sciences & Healthcare FY 2025

2025 Market Backdrop (UK & Europe)

2025 marked a selective recovery for UK and European life sciences amid an improving macro backdrop. Global venture funding into life sciences and healthcare rose **10% year-on-year (\$54bn to \$60bn)**, with **Europe up 28%**, while the UK remained flat at **£2.9b**, a constructive outcome given the tougher environment and higher 2023 base. Capital markets remained cautious but stabilising, with improving equity sentiment and declining interest rates beginning to support risk appetite. Easing financial conditions and clearer regulatory direction helped underpin confidence, even as geopolitical uncertainty and macro volatility persisted.

Biotech

Biotech investment remained highly selective but showed renewed momentum. Capital continued to concentrate in differentiated platforms and biotech **megadeals** across Europe, particularly in the UK, while **first financing rounds** driven by innovative technologies AI and platform technology showed resilience. Exit markets were uneven, with a quiet bineurotech IPO window (8 listings), but M&A activity accelerated, with fewer transactions and sharply higher deal values focused on scaled, de-risked assets. **UK policy developments—including the Life Sciences Sector Plan and a revised VPAG agreement** improved long-term visibility, while Europe advanced toward a more predictable, innovation-friendly regulatory framework supporting cross-border investment. Against this backdrop, oncology investment moderated and competitive pressure from China intensified, with around one-third of global licensing deals now originating from Chinese assets, even as improving capital markets and an AI-driven rotation are drawing generalist investors back toward life sciences and healthcare.

Med Device

European MedTech financing reached a **three year high in 2025**; but growth was **driven by capital concentration** rather than higher deal activity. Deal volumes held steady, while funding clustered into a small number of **larger, higher-conviction rounds**, with **AI increasingly embedded** across the top deals. First financing also reflected a **continued shift away from early technical risk**, with many of the largest rounds backing companies near approval or commercialisation, blurring the line between traditional early-stage and growth capital.

HealthTech

HealthTech **expands 29% YoY**, led by significant **mega deal activity in Europe** and **new highs in first financing activity (Page 21)**. As a standalone, the UK healthtech market was a bit muted, with significant deployment (e.g. Cera Care, Lindus Health), yet shrinking 17% YoY. The year did kick off significantly with mega deal announcements (e.g. Neko Health, Amboss) while the remaining year kept pace with an average of **£264M deployed/quarter** across the region.

Please reach out to us with your thoughts and for more details about our upcoming initiatives.



Glen Waters

Head of Tech & Life Sciences Banking
glen.waters@hsbc.com



Jamie Signal

Director, Biopharma, Diagnostics & Tools
jamie.signal@hsbc.com



Dominick Kennerson

Director, Business Development, Life Sciences & Healthcare
dominick.kennerson@hsbc.com



Paula Burke

Director, HealthTech & Medical Devices
paula.burke@hsbc.com



Helena Fraser

Vice President, Biopharma, Diagnostics & Tools
helena.fraser@hsbc.com

Venture funding and average deal size trends

Mega-deals drive up the UK & European equity pools: UK investment cools in the 2nd half as mega deals normalize

In 2025, Europe led the way with both average deal size and total life science venture funding deployed, **surging 28% YoY**.


- ◆ After a record setting 1H, the UK had a more rational 2H finishing effectively even with the prior year 2024.
- ◆ In the UK, total 1H venture financing was £1.8B compared to 2H at £1.1B – a decrease of 38%.
- ◆ Given the large concentration of biotech in the UK (60%), the 1H deals megadeals biotech continued but not at 1H levels. **For example, Isomorphic Labs funding in Q1 was the largest deal of the year - 41% larger than the 2nd largest deal.**

Given 2023's modest £2B, the new higher two-year threshold set in 2024 and maintained in 2025 is overall positive for the UK ecosystem.

Europe's mega deal pace, propped-up by companies such as **Neko Health** and **Amboss** were significant momentum builders for European funding.



Driven by megadeals, average deal size rose in the both Europe and the UK, 22% and 29%, respectively.



Note: Data via PitchBook through 15. December 2025, covering private, venture-backed investment.
Source: PitchBook, company websites, internal analysis..

TechBio UK & Europe FY 2025

Biopharma, Dx Tools First-
Financing Largest Financings
Most Active Investors
Biotech M&A 2025 Summary



Biopharma, Dx Tools First-Financing¹ largest financings

Platform leads total dollars in first financings in UK & Europe while Neurodegeneration leads in transactions

Stage at First Financing

Despite the visibility of late-stage in-licensed assets, **preclinical companies still dominated first financings**, accounting for **9 of the top 20 deals**, followed by **Phase II** and **Phase I** programs. This reflects continued investor confidence in companies spinning out of leading academic institutions, where strong biological rationale and platform innovation remain sufficient to attract large initial rounds even without clinical data.

Indication and Platform Focus

Platform companies were the largest category, representing **38% of the top 20 first financings**, highlighting continued investor appetite for multi-asset value creation and optionality. **Neuroscience also showed strong momentum**, with **9 total deals in the top 20**, representing **13% of total financings**, reflecting renewed confidence in differentiated neuro-biology and enabling technologies.

In contrast, **oncology accounted for only three deals totalling £38.6M**, representing just **3% of top-20 capital deployed**. Excluding the uncertain future trajectory of Isomorphics Labs, this decline supports broader global trends showing that investors were heavily overweight oncology in 2024 and are now awaiting meaningful exits and late-stage validation before re-entering the space at scale.

Overall, these patterns closely mirror trends observed in our global venture funding dataset.



In 2025, First Financings were led by preclinical platform and neuroscience companies, while oncology declined as investors prioritised scalable biology and awaited exits in crowded cancer markets.

#	COMPANY	INDICATION	STAGE	ROUND SIZE (£) ²	NEW INVESTOR(S)	LOCATION
1	Isomorphics Labs	Platform	Pre-Clinical	449M	Thrive Capital, GV, Alphabet	London, UK
2	Verdiva Bio	Metabolic/Obesity	Phase 1	327M	General Atlantic, Forbion, Orbimed, RA Capital, Logos, LYFE, Lilly Asia	Guildford, UK
3	Windward Bio	Respiratory	Phase 2	159M	Blue Owl, Harbour BioMed, Novo Holdings, Omega Funds, OrbiMed, Pivotal Bioventure, Qiming, Quan, RTW, SR One Capital	Basel, CH
4	ALCHEMAB THERAPEUTICS	Neuro	Phase 1	86.5M	DCVC, DHVC, Lightstone Ventures, Ono Venture, RA Capital	London, UK
5	ELEVARA MEDICINES	Auto-Immune	Phase 2	52.4M	Forbion, Monograph Capital, Sofinnova Partners	Altrincham, UK
6	OmniSpirant THERAPEUTICS	Drug Delivery	Pre-Clinical	33.3M	Enterprise Ireland	Galway, IE
7	Tribune Therapeutics	Platform	Pre-Clinical	30.9M	Industrifonden, Investinor, LifeArc Ventures	Stockholm, SE
8	TRIMTECH THERAPEUTICS	Neuro/Migraine	Pre-Clinical	25M	Cambridge Enterprise Ventures, Cambridge Innovation Capital, Eli Lilly, M Ventures, Pfizer Ventures, SV Health	Cambridge, UK
9	NovaGray	Dx Test	*	25M		Montpellier, FR
10	Ribocure Pharmaceuticals AB	Hematology	Phase 2	24.3M	Erik Selin (Angel), Jacob Torell (Angel)	Mölnådal, SE

Data from PitchBook through 15. December 2025, covering private, venture-backed investment.

Data Sources: PitchBook, company websites, internal analysis.

¹First-financing defined as Seed or Series A financing of \$2M+

². Exchange rate via reported funding currency to GBP as of date of financing

Biopharma, DxTools first-financing¹ largest financings

UK leads with most First Financings again; Go East to In-License Best-In-Class/First-In-Class

Geography of First Financings

The UK led European first financings with seven deals, reflecting the Golden Triangle's deep academic research base and proximity to specialist biotech investors. This was followed by a strong Nordic cluster with five deals, and an even distribution across the rest of Europe with one to two deals per country. This geographic concentration further underscores London and the broader UK ecosystem's growing role as Europe's primary hub for early-stage biotech formation.

Investor Participation

Top European life sciences VCs including Forbion, Novo Holdings, and SV Health were highly active in first financings during 2025. At the same time, leading US biotech investors — notably RA Capital and OrbiMed - were increasingly active in European rounds, attracted by valuation arbitrage and strong scientific assets.

Strategic and corporate participation also increased, with Pfizer and GV (Alphabet) participating in multiple financings, while Eli Lilly led three first-round investments, signalling growing engagement from Big Pharma and Big Tech at company formation. The most emblematic example remains Isomorphic Labs, backed by Google and Alphabet, illustrating continued convergence between AI, platform biology, and drug development.

Going East for Best-in-Class and First-in-Class Targets

In 2025, many of the largest first financings in the UK and Europe were driven by licensing deals with Chinese biotech companies, allowing Western startups to in-license clinically validated, late-stage assets at formation. This arbitrage leverages the speed and efficiency of the Eastern biotech ecosystem for early clinical development, while Western VCs and management teams advance programs through late-stage trials, regulatory approval, and commercialisation. Companies such as Verdiva (best-in-class GLP-1 for obesity), Elevara (first-in-class targeting fibroblast-like synoviocytes in rheumatoid arthritis), and Windward (best-in-class TSLP ligand for COPD) exemplify this model.



By entering large, established disease areas w/de-risked assets, this new class of biotechs are positioned for accelerated access to late-stage equity, product launches, and exits. **As a result, 2025 First Financings increasingly resembled traditional Series B rounds in capital raised and asset maturity.**

#	COMPANY	INDICATION	STAGE	ROUND SIZE (£) ²	NEW INVESTOR(S)	LOCATION
11	 Arctic Therapeutics	Neuro	Phase 2	22.1M	21 Impact Labs, Consortium, Kaldbakur, Nancy Lurie Marks Family Foundation, Sanos Group	Reykjavik, IS
12	 LAVEROCK THERAPEUTICS	Platform	Pre-Clinical	20.3M	Calculus Capital, Eli Lilly, Eos Advisory, Maven Capital Partners UK, Mercia Ventures, Norcliffe Capital	Stevenage, UK
13	 Draig Therapeutics	Neuro	Phase 2	20M**	SV Health Investors, Intermediate Capital Group	Cardiff, UK
14	 Commit Biologics	Platform	Pre-Clinical	18M	Bioqube Ventures, Korys Investments, Novo Holdings	Aarhus C, DK
15	 EvlaBio	Renal	Pre-Clinical	17.9M	Adbio Partners, BI Venture Fund, High-Tech Gründerfonds, Khanu Management, Kurma Partners, Lead Discovery Center, NRW Bank	Zurich, CH
16	 Mondego Bio	Oncology	*	17.3M	Biovance Capital Partners, OrbiMed, Torrey Pines Investment	Lisbon, PT
17	 NEUMIRNA Therapeutics	Neuro	Pre-Clinical	16.6M	Angelini Ventures, Invivo Partners	Copenhagen, DK
18	 Stratifai	Oncology	*	10.9M	Alven Capital Partners, Heliad, Lars Langush, Picus Capital, Rubin Ritter	Dresden, DE
19	 AI-Stroke	Neuro	*	11M	Newfund Management	Montpellier, FR
20	 NANOLIGENT	Oncology	Pre-Clinical	10.4M	Clave (Pamplona), INNVIERTE SICC, Inveready Asset Management	Barcelona, ES

Data from PitchBook through 15. December 2025, covering private, venture-backed investment.

Data Sources: PitchBook, company websites, internal analysis.

1 First-financing defined as Seed or Series A financing of \$2M+

2. Exchange rate via reported funding currency to GBP as of date of financing

**Draig Seed announced in April 2025, with Series A June 2025 (Slide 9).

Biopharma first-financing¹ by primary indication

Platform and Neurodegenerative Steal the Show

Platform Grows While Neurodegeneration Rides a Perfect Storm of Tailwinds in First Financings

Platform companies again captured the largest share of VC dollars in 2025, driven by mega-deals such as **Isomorphic Labs (£449M)** and supported by smaller financings including **Laverock (£20M)** and **Commit (£18M)**. This reflects continued investor preference for scalable discovery engines that can generate multiple assets and long-term optionality.

Metabolic disease saw a sharp resurgence, largely driven by the outlier first financing of **Verdiva** in obesity, underscoring sustained investor conviction in next-generation GLP-1 and metabolic mechanisms despite increasing competitive density.


Neurodegenerative disease also experienced a flurry of financings, led by **Alchemab (£84M)**, **Trimtech (£25M)**, and **Draig Therapeutics**, which later in the year raised a substantially larger follow-on round. Momentum in neuroscience at the first-financing stage appears to be driven by aging demographics, recent FDA breakthrough approvals, commercial success of new therapies (including **BMS's Cobenfy**, **Roche's Ocrevus**, and **Novartis's Kesimpta**), and renewed M&A activity highlighted by **Novartis's \$12B acquisition of Avidity**.

In parallel, **AI-driven platforms for Neuro are improving target identification by translating genomic and proteomic signatures into druggable opportunities**, reducing early biological risk in neurologic indications and making the category more attractive for early-stage venture investment.



Neuroscience surged back into favour in 2025 fuelled by AI-enabled target discovery, regulatory momentum, and high-profile commercial and M&A validation from Big Pharma.

UK & European Lead Financing by Top Value (£) Indications



Note: Data via PitchBook through 15. December 2025, covering private, venture-backed investment.
Source: PitchBook, company websites, internal analysis..

Biopharma, Dx/Tools largest financings (all deals)

Late-stage oncology start-ups ring the bell; innovation spreads across UK/Europe with clusters in the UK and Switzerland

Stage

In 2025, the top 20 financings showed a bell-shaped distribution by development stage, with most companies in Phase II and later, followed by preclinical programs. This reflects typical funding trajectories, where the largest rounds are raised near late-stage value inflection points, exemplified by Tubulis' £268M round for its late-stage ADC program. Still, five companies (25%) were preclinical, underscoring continued investor willingness to fund compelling science ahead of clinical proof.

Disease Indication

Deal activity was well diversified across major disease areas, with no more than two deals in most indications. Oncology follow-on activity was intensive, accounting for six deals (30%), suggesting investors are concentrating capital in known assets while awaiting exits before making new category bets.

Notably, gene therapy can still attract large rounds - SpliceBio (Barcelona, Spain; backed by EQT Life Sciences), whose differentiated ophthalmology gene therapy attracted a mega-round outside oncology.

Geography

The UK led financing activity, while Switzerland captured four of the top 20 deals (20%), reflecting strong scientific heritage, proximity to global pharma, and favourable macro conditions that continue to attract biotech capital.

Investor Participation

Investor participation spanned VCs, crossovers, and strategics. The most active VCs were Forbion (4), RA Capital (3), Novo Holdings (3), Sanofi Ventures (2), and SR One (2). Strategic investors, led by Eli Lilly or Lilly Asia (4 deals), alongside Google, Alphabet, and Amgen Ventures, signal growing confidence in IPO reopening and M&A ongoing in 2026.



With 20% of large deals, Switzerland's pro-biotech policies, deep capital, & proximity to Big Pharma for M&A set the benchmark for biotech ecosystems in Europe.

#	COMPANY	INDICATION	STAGE	ROUND SIZE (£) ²	NEW INVESTOR(S)	LOCATION
1	 Isomorphic Labs	Platform	Pre-Clinical	449M	Thrive Capital, GV, Alphabet	London, UK
2	 Verdiva Bio	Metabolic/Obesity	Phase 1	327M	General Atlantic, Forbion, Orbimed, RA Capital, Logos, LYFE, Lilly Asia	Guildford, UK
3	 TUBULIS	Oncology	Phase 2	268M	Ascenta Capital, Venrock, Wellington Management	Planegg-Martinsried, DE
4	 Windward Bio	Respiratory	Phase 2	159M	Blue Owl, Harbour BioMed, Novo Holdings, Omega Funds, OrbiMed, Pivotal Bioventure, Qiming, Quan, RTW, SR One Capital	Basel, CH
5	 NUMAB	Platform	Phase 1	159M	BlackRock, BVF Partners, Cormorant Asset Management, Forbion, HBM Healthcare, Novo Holdings, Octagon Capital, RTW Investments	Horgen, CH
6	 HEM.B	Hematology	Phase 2	117.2M	Avoro Ventures, Sofinnova Partners	Frederiksberg, DK
7	 azafaros	Orphan/Rare Disease	Phase 2	113M	Jeito, Pictet, Seroba Life Sciences, Forbion	Leiden, NL
8	 AAVANTGARDE	Ophthalmology	Phase 2	105.7M	Amgen Ventures, Athos Capital, British Columbia Investment Management, CDP Venture Capital, NEVA SGR, Schroders, Sixty Degree Capital, Willett Advisors, XGEN Venture	Rome, IT
9	 Draig Therapeutics	Neuro	Phase 2	103.7M	Access Industries, Canaan Partners, Sanofi Ventures, Schroders Capital, SR One Capital Management	Cardiff, UK
10	 SPLICEBIO	Ophthalmology	Phase 1/2	100M	EQT Life Sciences, Roche, Sanofi Ventures	Barcelona, ES

Data from PitchBook through 15. December 2025, covering private, venture-backed investment.

Data Sources: PitchBook, company websites, internal analysis.

1 First-financing defined as Seed or Series A financing of \$2M+

2. Exchange rate via reported funding currency to GBP as of date of financing

Biopharma, Dx/Tools largest financings (all deals)

From Needles to Pills: Delivery Innovation Drives Deal Momentum

Novel delivery platforms push valuations to new levels...

In 2025, investor interest shifted toward innovative drug delivery systems, reflecting a push to expand the reach and commercial potential of biologic and cell-based therapies.

This was evident in M&A activity around next-generation platforms, including **in vivo cell therapy** (e.g., GSK's ~\$1B acquisition of EsoBiotec), followed by **San Diego-based Capstan Therapeutics' in vivo cell therapy platform leveraging targeted lipid nanoparticle (tLNP) technology**, with validation from **AbbVie's ~\$2.1B acquisition**. These deals highlight demand for more precise and scalable delivery of complex therapies.

Investors also focused on **converting biologics into oral therapies** in large chronic disease markets. **Verdiva's oral GLP-1 platform** attracted significant capital, while **Orbis Medicines**, backed by **Novo Holdings and Forbion**, is developing oral macrocycles as alternatives to injectable biologics.

Public markets reinforced this shift when **Boston-based Kymera's Phase II data drove a ~42% stock increase, lifting its market capitalization to approximately \$5.6B**, positioning the program as a potential "oral Dupixent."



Investors are backing delivery platforms that transform biologics into scalable, patient-friendly therapies - with oral drugs emerging as the next major funding cycle.

#	COMPANY	INDICATION	STAGE	ROUND SIZE (£) ²	NEW INVESTOR(S)	LOCATION
11	 GLYCOERA	Platform	Pre-Clinical	97.4M	Agent Capital, BMS Foundation, Catalio Capital Management, LifeArc Ventures, MP Healthcare Venture Management, Novo Holdings, Qatar Investment, Roche Ventures, Sixty Degree Capital	Zurich, CH
12	 ADCYTHERIX	Oncology	Pre-Clinical	93.5M	aMoon Fund, Andera Partners, Angelini Ventures, Bpifrance, Kurma Partners, Surveyor Capital	Marseille, FR
13	 CellCentric	Oncology	Phase 2	89.7M	Avego Management, Forbion	Cambridge, UK
14	 artios DNA DAMAGE RESPONSE	Oncology	Phase 2	86.5M	Janus Henderson Investors, Piper Heartland, RA Capital Management	Cambridge, UK
15	 ALCHEMAB THERAPEUTICS	Neuro/Oncology	Phase 1	84.3M	DCVC, DHVC, Eli Lilly, Lightstone Ventures, Ono Venture Investment, RA Capital Management	London, UK
16	 BEREN THERAPEUTICS	Platform	Phase 1	79.5M*	Roquette	Bonn, DE
17	 orbis MEDICINES	Platform	Pre-Clinical	74.6M	Cormorant Capital, Eli Lilly and Company, Export Development, New Enterprise Associates	Frederiksberg, DK
18	 NanoPhoria bioscience	Cardiovascular	Pre-Clinical	72.6M	CDP Venture Capital, Panakes Partners, XGEN Venture	Milan, IT
19	 NUCLIDIUM	R&D Tool	*	71.9M	Angelini Ventures, Bayern Kapital, Deep Tech & Climate Funds, Eurazeo, Highlight Capital, NEVA SGR, NRW.Bank, Vives Fund, Wellington Partners	Basel, CH
20	 trogenix	Oncology	Pre-Clinical	70M	Calculus Capital, Eli Lilly, LongeVC, Meltwind Advisory, The Brain Tumor Investment Fund	Edinburgh, UK

Data from PitchBook through 15. December 2025, covering private, venture-backed investment.
 Data Sources: PitchBook, company websites, internal analysis.
 1 First-financing defined as Seed or Series A financing of \$2M+
 2. Exchange rate via reported funding currency to GBP as of date of financing

Bio-pharma/tech and Tools most active investors

Venture investors, funds and corporates for UK + European HQ Companies

Most Active Sector Investors, All Investors (incl. Early Stage, Later Stage) >\$2M, ≥2x Investments



Note: Data via PitchBook through 15. December 2025, covering private, venture-backed investment.
Source: PitchBook, company websites, internal analysis..

UK & EU Biotech M&A 2025 Summary

Top M&A Transactions during FY2025

Company → Acquirer	Disease area	Country	Deal Size (USD,M)	Deal Quarter	Stage
Verona Pharma → MSD	Respiratory	UK	10,000	Q3	Commercial
Merus → Genmab	Oncology	Netherlands	8,051	Q3	Clinical
VarmX → CSL	Haematology	Netherlands	2,166	Q3	Clinical
Avadel → Alkermes	Neurology	Ireland	1,921	Q4	Clinical
ViceBio → Sanofi	Respiratory	UK	1,689	Q3	Clinical
CureVax → BioNTech	Oncology	Germany	1,294	Q3	Clinical
Araris → Otsuka	Oncology	Switzerland	1,175	Q1	Pre-clinical
EsoBiotec → AstraZeneca	Oncology	Belgium	1,000	Q1	Clinical

Eight Companies Generating over \$27B in Value



Trending 2025 Merger & Acquisitions Themes

- ◆ Pleasingly, we saw an uptick in \$1bn+ M&A deals in 2025 compared to 2024 (8 vs 6) although we note a lack of mid stage M&A transactions (\$100m-\$1bn) in 2025 compared to 2024 (only 1 deal compared to 7 in 2024 e.g. Exscientia for \$650m).
- ◆ We believe this phenomenon is driven by an increase in a competitive bidding process by pharma for top-tier assets with later stage assets unsurprisingly commanding increasingly higher valuations.
- ◆ Oncology assets continued to lead the way although we saw two large acquisitions in the respiratory space.
- ◆ Pharma continue to look for later stage assets, although we have witnessed some earlier stage biotechs also being acquired (e.g. ViceBio).
- ◆ Of significance we witnessed the UK's largest biotech acquisition when MSD acquired Verona Pharma for \$10bn.
- ◆ We saw deals close from across the UK and EU with companies being acquired from UK, Germany, Netherlands as well as Ireland, Switzerland & Germany.
- ◆ Whilst not significant in itself we did see a marked improvement in the XBI which increased 34% during 2025 (and has further increased leading into 2026).
- ◆ Whilst not reported in our annual figures the UK biotech industry could also take credit for the acquisition of obesity drug Metsera for \$10bn by Pfizer given its origins from Imperial.
- ◆ We also note the acquisition in early 2026 of Oxford based & pre-clinical oncology company Dark Blue Therapeutics for up to \$840m by Amgen.

Summary

- ◆ As a team, we remain confident in the continued improvement in both Global and UK biotech sectors thanks to an uptick in M&A, a much-improved XBI, some notable VC fundraisings and a potential IPO return towards the end of 2026.

Note: Data via PitchBook through 15. December 2025, covering private, venture-backed investment.
Source: PitchBook, company websites, internal analysis..

TechBio UK & Europe FY 2025

2023 – 2025 Trends, Value,
Indication Highlights FY 2025:
Notable Deals, and Key
Investors



Helena Fraser

Vice President, Biopharma, Diagnostics &
Tools

helena.fraser@hsbc.com

TechBio Highlights UK & Europe 2025

UK as a leading techbio hub, centered around the “Golden Triangle”

2025 Key TechBio Themes UK & Europe

- ◆ Isomorphic Labs secured \$600m in a single financing round, an amount often attributed to later-stage companies.
- ◆ Geographically the UK continues to establish itself as a credible Techbio hub with London, Oxford and Cambridge hosting a growing cluster of companies including Isomorphic Labs, CHARM, Alchemab, and Relation.
- ◆ Investment activity in 2025 was notably more concentrated, with fewer deals absorbing larger pools of capital.


The year’s largest financings were led by established investors including Novo Holdings, RA Capital, OrbiMed, Sofinnova, Thrive Capital, Alphabet, GV, NEA, and SROne.

Overall, activity reflects sustained investor appetite for **data-driven** and **AI-enabled biology**. Investors are increasingly drawn to opportunities that combine validated biological endpoints and clear market potential with **next-generation, data-centric discovery** and **development models**.



Investment trends in 2025 signal a maturing ecosystem where capital is deployed selectively to turn biology into actionable programmes.

TechBio UK/Europe venture funding (£,M)



Top UK/Europe TechBio Hubs 2025

City	Total Raised (£,M)	Deal Count
London, UK	674.8	9
Frederiksberg, DK	71.6	1
Lausanne, CH	54.0	2
Paris, FR	47.3	3
Glasgow, UK	42.7	2

Note: Data via PitchBook through 15. December 2025, covering private, venture-backed investment.
Source: PitchBook, company websites, internal analysis..

TechBio UK & European FY 2025

Top 10 Deals

AI is increasingly industrialising drug discovery across complex disease areas.











Investor focus has shifted towards **AI-native, platform-led companies rather than single-asset stories**, reflecting strong support for teams that pair deep biological expertise with proprietary computational infrastructure. The strategic emphasis is on building scalable, repeatable discovery engines capable of generating multiple high-value programmes over time.

Value creation in this segment is currently underwritten by private capital. With a significant concentration of financings at **Series A**, 2025 saw unprecedented investor support for preclinical platforms. Within this landscape, **Isomorphic Labs stands out as a notable outlier**, backed by Alphabet, Thrive Capital and GV, and widely regarded as a **flagship** example of **AI-driven small-molecule** discovery.

Across the landscape, investors backed innovative platform technologies and disease focused pipelines with **neuroscience, oncology, and immunology** emerging as the most prominent areas. Investments reflect sustained demand for modalities capable of addressing **high-unmet need**, large addressable markets and biologically complex targets where **data-driven approaches provide meaningful advantages**.



Investors are concentrating capital where AI functions as the lab, the hypothesis engine, and execution. Redefining discovery, design development and delivery.

#	COMPANY	INDICATION	STAGE	ROUND SIZE (£) ²	NEW INVESTOR(S)	LOCATION
1	 Isomorphic Labs	Platform	Pre-Clinical	449M	Thrive Capital, GV, Alphabet	London, UK
2	 ALCHEMAB THERAPEUTICS	Neuro/Oncology	Phase 1	84.3M	DCVC, DHVC, Eli Lilly, Lightstone Ventures, Ono Venture Investment, RA Capital Management	London, UK
3	 crbis MEDICINES	Platform	Pre-Clinical	74.6M	Cormorant Capital, Eli Lilly and Company, Export Development, New Enterprise Associates	Frederiksberg, DK
4	 CHARM ^{TX}	Platform	Pre-Clinical	59.4M	New Enterprise Associates, Nvidia, SR One Capital	London, UK
5	 BIOPTIMUS	R&D Tool	-	50M	8VC, Hawktaill, Insight Partners (Asheville), Rockspring, Wing Venture Capital	Glasgow, UK
6	 Chemify	Platform	Pre-Clinical	48.9M	Alexandria Venture Investments, Arthos Capital, Earlybird Venture Capital, LifeLink Ventures, ND Capital, Sofinnova Partners	Lausanne, CH
7	 RELATION	Platform	Pre-Clinical	41.7M	-	London, UK
8	 HAYA Therapeutics	R&D Tool	-	33.2M	Andera Partners, Boom Capital Ventures, Emmanuel Cassimatis, Hitachi Ventures, Pomifer Capital, Sunrise Capital, Thomas Wolf	Paris, FR
9	 Latent Labs	R&D Tool	-	32.3M	Aidan Gomez, AWS Startups, Flying Fish Partners, Isomers Partners, Jeff Dean, Mateusz Staniszewski, Radical Ventures, SBXi, Sofinnova Partners	London, UK
10	 Arctic Therapeutics	Neuro	Phase 2	22.1M	21 Impact Labs, Consortium, Kaldbakur, Nancy Lurie Marks Family Foundation, Sanos Group	Reykjavik, IS

Data from PitchBook through 15. December 2025, covering private, venture-backed investment.

Data Sources: PitchBook, company websites, internal analysis.

1 First-financing defined as Seed or Series A financing of \$2M+

2. Exchange rate via reported funding currency to GBP as of date of financing

TechBio Most Active Investors UK & Europe

Most Active Sector Investors, All Investors (incl. Early Stage, Later Stage) >\$2M



Med Device

First-Financing Venture Investment Activity, FY 2025 Medical Device Active Investors Top Medical Device Venture Deals 2025



Paula Burke

Director, HealthTech & Medical Devices
paula.burke@hsbc.com

European Medical Device First-Financings 2025

- ◆ First financing activity in European MedTech softened and concentrated in 2025, in contrast to the USA, where activity has remained stable over the past three years. European funding clustered sharply within the **top ten transactions**, which **accounted for over 70% of total first financing capital**, reflecting heightened selectivity and evolving investor dynamics.
- ◆ Compared with the US, **Europe continues to face structural frictions**, including a shallower pool of specialist MedTech investors, and longer, less predictable regulatory timelines. At the same time, global **MedTech investors are increasingly prioritising later stage entry**, where clinical, regulatory and exit visibility are clearer, shifting the risk-reward balance across the funding lifecycle. While Europe can continue to generate high-quality innovation, even first financings now often support companies already approaching commercial or regulatory inflection points, rather than purely early development programmes. This is evident **in the top ten transactions, where several companies were already commercial or close to approval**.
- ◆ **Imaging and surgical** technologies remain the **most consistently funded** at entry, albeit below prior peak levels. **Cardiovascular** investment resumed in 2025, driven by a small number of financings rather than a broad-based increase in investment. **Artificial intelligence (AI) featured unevenly** across the top ten first financing rounds, spanning both AI-led and AI-adjacent technologies, often supporting product differentiation rather than defining the core device proposition.
- ◆ The **most pronounced** first financing **pullbacks** were **in orthopaedics and non-invasive monitoring**, reflecting longer development timelines, reimbursement hurdles and scale up complexities.



Several of the top 10 first financings backed commercial or near approval companies, blurring the line between traditional early-stage and growth MedTech financing in Europe.

Top 10 First-Financing League Table 2025 MedTech Venture Financing

#	COMPANY	MEDTECH SUBSECTOR	DEAL SIZE £M ¹	NEW INVESTOR(S)	COMPANY HQ
1	VARDIS SWITZERLAND	Oral: Tooth Protection	28.3	OrbiMed	Zug, CH
2	SCAF HOLOGRAM	Imaging: Surgery	9.57	Haventure, MinMax Medical, eCential Robotics, Surosh	Saint-Martin-d'Hères, FR
3	ADTEC HEALTHCARE LIMITED	Dermatology: Wound care	8.7	AIPO Fund, SG Biomedical	London, UK
4	BIOMIMETIC INNOVATIONS	Surgical: Skeletal & Soft Tissue	6.7	Sanara MedTech	Shannon, IE
5	CIRCLESAFE	Cardiovascular: Ablation Support	6.7	Odyssee Venture, Bpifrance, Région Sud Investissement	Marseille, FR
6	APPROXIMA tricuspid therapy	Cardiovascular: tricuspid regurgitation	6.1	ENEA Tech e Biomedical and Panakès Partners	Seregno, IT
7	SURGIFY FOR SAFER BONE SURGERY ⁴	Surgical: Bone Cutting	5.9	ZEISS Ventures, Lednil, EIC Fund, Cascara Ventures	Espoo, FI
8	APEX DIGITAL	Oral: Prosthetics	5.6	Generis Capital Partners	Caen, FR
9	Plasmacure	Dermatology: Wound healing	5.1	Venture Medical, Coöperatie VGZ, Noaber, Stichting Triade	Nijmegen, NL
10	osaa INNOVATION	Surgical: IV therapy	4.6	Undisclosed	Ballerup, DK

¹Exchange rate from funding currency to GBP as of date of financing

² Raised a \$50m follow-on financing in July 2025 (not included)

³Raised €11m debt alongside equity (not included)

⁴ Deal size includes debt (undisclosed amount)

Medical Device: Europe's Most Active Investors 2025

Most Active Sector Investors, All Investors (incl. Early Stage, Later Stage) >\$2M, ≥2x Investments



- ◆ European MedTech financing increased materially in 2025, reaching its **highest level of the past three years**. Growth was driven by **capital concentrating** into a small number of large, high-conviction transactions, with **the top twenty rounds accounting for close to 80% of total funding**. Deal volumes remained broadly stable, reinforcing a shift toward more selective rather than volume-driven.
- ◆ Geographically, investors concentrated funding across six core European markets. Finland emerged as the largest market by capital raised, driven by Oura's ~\$900m Series E. Excluding this outlier, **Switzerland and the UK continued to anchor European MedTech investment**, combining strong funding volumes with sustained deal flow, followed by France, the Netherlands and Ireland.
- ◆ By indication, investor capital clustered most strongly around **non-invasive monitoring (NIM) and surgical**, both heavily represented within the top ten (next page). NIM also recorded the highest deal volume, reflecting broad investor appetite, particularly at later stages. Surgical funding increased materially despite fewer rounds, pointing to larger cheque sizes.
- ◆ Beyond these, capital deployment was most pronounced in **cardiovascular, neuro, dermatology, drug delivery and oral**. Deal activity accelerated in cardiovascular, imaging and ophthalmology, while orthopaedics continued to attract meaningful investment, albeit at lower aggregate levels and with fewer financings year on year.



Deal activity held steady, but capital skewed towards later-stage assets with clearer pathways to scale and exit.

Note: Data via PitchBook through 15. December 2025, covering private, venture-backed investment.
Source: PitchBook, company websites, internal analysis..

European Medical Device Notable Financings FY 2025

Top 10 League Table 2025 MedTech Venture Financing

#	COMPANY	MEDTECH SUBSECTOR	DEAL SIZE £M ¹	NEW INVESTOR(S)	COMPANY HQ
1	 ŌURA	NIM: Consumer Health	674.3	ICONIQ Capital, Atreides Capital, Whale Rock Capital	Oulu, FI
2	 OrganOx ² living organs for life	Surgical: Organ transplantation	121.4	HealthQuest Capital, Sofina, Soleus Capital and Avidity Partners	Oxford, UK
3	 Distalmotion ³	Surgical: Robotics	113.7	Existing investor round	Lausanne, CH
4	 CMR SURGICAL	Surgical: Robotics	100.1	Existing investor round	Cambridge, UK
5	 CeQur	Drug Delivery: Insulin	95.4	Existing investor round	Luzern, CH
6	 FIRE1	NIM: Heart Failure	95.4	Polaris Partners, Elevage Medical Technologies, Longitude Capital, Sands Capital	Dublin, IE
7	 ViCentra ⁴ Home of Kaleido.	NIM: Closed Loop Insulin System	62.9	Innovation Industries	Utrecht, NL
8	 ProVerum	Urology: Prostate	59.6	MVM Partners, OrbiMed, Ireland Strategic Investment Fund	Dublin, IE
9	 WANDERCRAFT	Orthopaedic: Robotic exoskeleton	55.4	Renault Group, PSIM fund, Teampact Ventures	Paris, FR
10	 CUTISS personalized skin	Dermatology: Skin Graft	51.6	Swisspreneur, Family Offices	Schlieren, CH

- ◆ While the **top ten transactions captured over 60% of total funding**, activity beyond the largest rounds also strengthened year on year, pointing to greater depth at the upper end of the market.
- ◆ These transactions reinforce a **clear investor preference for later-stage, commercial assets reshaping the standard of care**, with most companies either revenue generating or approaching commercialisation. This underscores the continued shift away from early-stage risk towards platforms with clearer commercial and reimbursement pathways. If sustained, **this dynamic challenges long term pipeline formation in European MedTech**, even as innovation remains strong.
- ◆ **Across the top ten, a significant portion of companies were AI-led or AI-adjacent**, highlighting the critical role AI can play in advancing MedTech value creation by optimising workflows and strengthening clinical and commercial differentiation.
- ◆ **Strategic investment was also a defining feature across the top ten**, spanning global MedTech and industrial players including Terumo, Johnson & Johnson, Medtronic, Dexcom and Renault. Their presence reflects a broader "string of pearls" strategy of engaging earlier through investment to secure the most differentiated assets, address offering gaps and manage future competitive risks, further reinforcing M&A as the dominant exit pathway in a market where public exits remain limited.



Overall, 2025 European Medtech venture financing reflects a market prioritising quality over quantity, with capital deployed where technical risk is lower, commercial visibility is higher and strategic value is clearer.

¹ Exchange rate from funding currency to GBP as of date of financing

² Acquired by Terumo in October 2025

³ Secured strategic investment from Johnson & Johnson, through its corporate venture arm in January 2026

⁴ Raised an additional \$13m (£9.7m) in January 2026 from Innovation Industries, ROM Utrecht Region, Venturing Tech.

Healthtech

Early-stage venture investment
activity & value pools

Top 10 HealthTech League Table

FY 2025 Active HealthTech
Investors



Dominick Kennerson

Director, Business Development,
Life Sciences & Healthcare

dominick.kennerson@hsbc.com

Early stage healthtech venture investment activity

UK & Europe Healthtech first financing trends

2025 first financings seem to be taking on a new trajectory. While the post-pandemic era has created market movement toward a more **risk-off early-stage investor market**, this approach seems to have set trend: to more functionally **resilient financial infrastructure**, more **meaningful early-stage valuations**, and therefore more **meaningful early-stage funding**.

We're now seeing early-stage companies with not only early grant funding, but sometimes significant 7-figure revenues (or ARR). This **bootstrap-to-millions mentality**, on the back of founder delayed gratification, seems to have created significant funding at the top of the market. Reflecting this trend, companies (adjacent table) such as **SheMed (UK)**, **Mycellen (HU)**, and **Evaro (UK)** may represent a new breed of founder success, where even Series B competitors take note of these double-digit million healthtech fundraising sums.

It may also be that UK/EU healthtech founders are now thinking of the **"one and done"** fundraise. For example, if the founder market knows that Series B represents a high-bar, they already have meaningful revenue, trending to EBITDA+, and a significant Series A cash cushion, then why take further dilution in a future venture funding round? And in that scenario **what role should runway extension, via non-dilutive debt financing, play into the significant Series A fundraise?**


While the UK continues to hold top-trend on first financing quantum, the wider data set (Slide 22) may suggest some slippage from UK dominance as a percentage of the fundraising market. While provider operations/workflow companies have been dominating market activity globally, **Germany sits atop the European funnel with 3 companies** in our healthtech Top 10 First Financing deals.

HealthTech First Financing		2023	2024	2025
	Count (n)	54	43	58
	Total Raised (£,M)	176.2	160	283.4
	Avg Raised (£,M)	3.3	3.7	5.8



With a 77% YoY increase in deployment and upsize on average funds raised, 2025 may become known as the year of the new Series A.

Early stage venture funding (£,M)



Top 10 First Financing HealthTech Value Pools	Medication Management		Alternative Care	
		£ 20M TOTAL RAISED		£ 7.8M TOTAL RAISED
	Workflow		Healthcare Navigation	
	 	£ 25.3M TOTAL RAISED		£ 11.9M TOTAL RAISED
	Health & Wellness		Clinical Trials	
	 	£ 76.1M TOTAL RAISED	 	£ 15.3M TOTAL RAISED

Data from PitchBook through 15. December 2025, covering private, venture-backed investment.

Data Sources: PitchBook, company websites, internal analysis.


¹First-financing defined as Seed or Series A financing of \$2M+

². Exchange rate via reported funding currency to GBP as of date of financing

UK & European HealthTech Notable Financings 2025

Top 10 League Table for 2025 HealthTech Venture Financing

#	COMPANY	HEALTHTECH SUBSECTOR	ROUND SIZE £M ²	ROUND LABEL	NEW INVESTOR(S)	COMPANY HQ
1	NEKO	Wellness & Education: Education & Wellness	210	Series B	Lightspeed Venture Partners	Stockholm, SE
2	AMBOSS	Wellness & Education: Medical Education	201	-	Burda Principal Investments, KIRKBI, Lightrock, M&G, Project A	Berlin, DE
3	Cera ⁺	Alternative Care: Primary Care	119.9	Series C1	BDT & MSD Partners, Pledge Ventures, Wcap	London, UK
4	Nabla	Provider Operations: Workflow	59	Series C	DST Global, Highland Europe, HV Capital Manager	Paris, FR
5	LindusHealth	Clinical Trials: Clinical Trial Enablement	44.6	Series B	Balderton Capital, SC Nation Services, Visionaries Club	London, UK
6	NElly	Provider Operations: Workflow	41.6	Series B	Cathay Innovation, eightyseven ventures, Heliad	Berlin, DE
7	voize	Provider Operations: Workflow	37.8	Series A	Balderton Capital	Berlin, DE
8	SheMed [®]	Wellness & Education: Health & Wellness	37.3	-	-	London, UK
9	MCellen	Wellness & Education: Health & Wellness	37.4	-	Obuda Uni Venture Capital	Pest, HU
10	Tandem	Provider Operations: Workflow	36.7	Series A	Kinnevik, Visionaries Club	Stockholm, SE



UK & Europe 2025 HealthTech

- While the overall HealthTech pie continues to grow (~67% growth 2023 – 2025), we'll continue to keep close eye on the United Kingdom's slice into 2026. The YoY healthtech decrease may be reflecting the wave of investor interest in the country's medtech sector or may be reflecting the Q3 stall also experienced in the biotech sector.
- The European mega rounds have been able to support a **70% YoY increase** of funds flowing through the region. While London continues its status as healthtech hub, Berlin is not to be outdone on frequency and fundraising depth alike.
- With **Neko**, **Amboss**, and **Cera** all announcing rounds in Q1 2025 funding surged to a **quarterly high of £793M**. The rest of the year paced a bit more moderately to £264M/quarter.
- Glaringly, the European companies at the top of the fundraising funnel are now reflecting market resilience alongside the global trend in **provider operations workflow solutions** (noted in our 1H 2025 report as a watch sector).
- While the 2024 HealthTech Top 10 was dominated by the Series C/D rounds, this new wave of deeper-pocketed funding suggests that we will have to track this vintage for some time in the context of any exit activity. The proverbial question of "where to list" may be developing in the minds of more than several founders in the region (e.g. vintage 2022 late stage healthtech).

Data from PitchBook through 15. December 2025, covering private, venture-backed investment.
 Data Sources: PitchBook, company websites, internal analysis.
¹First-financing defined as Seed or Series A financing of \$2M+
². Exchange rate via reported funding currency to GBP as of date of financing

UK & Europe HealthTech Most Active Investors

Active HealthTech Investors All Investors

Most Active Sector Investors, All Investors (incl. Early Stage, Later Stage) >\$2M, ≥2x Investments



Note: Data via PitchBook through 15. December 2025, covering private, venture-backed investment.
Source: PitchBook, company websites, internal analysis.

UK Regional Highlight: “OxBridge”

Key Investment Trends covering “Golden Triangle” gems




Jamie Bignal

Director, Biopharma, Diagnostics & Tools
jamie.bignal@hsbc.com


UK Regional Highlight: Cambridge & Oxford Life Sciences & Healthcare

“OxBridge” Venture Funding Highlights FY2025

Cambridge-sourced venture funding for life sciences and healthcare companies



Oxford-sourced venture funding for life sciences and healthcare companies



Top 5 Cambridge Funding Rounds Life Sciences & Healthcare FY2025

Company	Indication	Deal Size (£,M) ²	Deal Quarter	Series
CMR Surgical	Surgical	101.6	Q2	Series D2
CellCentric	Oncology	89.7	Q2	Series C
artios	Oncology	86.5	Q4	Series D
T-Therapeutics	Oncology	67.8	Q4	Series A
maxion therapeutics	Platform	58.1	Q1	Series A

Top 5 Oxford Funding Rounds Life Sciences & Healthcare FY2025

Company	Indication	Deal Size (£,M) ²	Deal Quarter	Series
OrganOx	Surgical	107.8	Q2	Later Stage
ULTROMICS	Dx Analytics	47.9	Q3	Series C
accession therapeutics	Oncology	30.5	Q4	Later Stage
BRAINOMIX	Dx Analytics	18.6	Q1	Series C
scripta	Neuro	10.3	Q4	Seed

Trending 2025 Merger & Acquisitions Themes

Worldwide, few innovation corridors carry the same gravitas as Oxford and Cambridge, UK (colloquially referred to as “OxBridge”). In market, we sometimes hear these distinct regional hubs sometimes exchange in jest on who leads, so we put the data to the test.

- ◆ Both Cambridge and Oxbridge boast a life science “mega deal” (over £100M), and combined the dual regions were able to **amass over \$1B (~£830M)** in venture funds raised. Notably, we did not include acquisition values, which would have added that much more value to a booming scene. For example, OrganOx was able to exit at £1.1B, while another Oxford darling in **Beckley Psytech** was able to tout a mid-year exit at **£292M (>10x its reported fundraising target)**.
- ◆ At first-blush, we also note the Cambridge proclivity to Biotech (capturing 60% of fund raised), and the Oxford ecosystem for Med Device (nearly half of funds raised at 48%).
- ◆ It seems as if only more than several investors (8) have deployed “OxBridge” capital with some frequency, of note:



Data from PitchBook though 15. December 2025, covering private, venture-backed investment.
 Data Sources: PitchBook, company websites, internal analysis.
¹First-financing defined as Seed or Series A financing of \$2M+
²Exchange rate via reported funding currency to GBP as of date of financing

Healthcare Perspectives

UK Life Sciences & Healthcare 1H 2025 and 2H 2025/2026 Outlook



Biotech, Diagnostics/Tools

2026: Africa, IPOs, and AI Fuel a Global Biopharma Recovery

In 2026, global biopharma markets shift decisively from recovery to expansion, powered by 2025's frenetic M&A activity and an AI-driven rotation as specialist investors lean in, generalists return, and the Magnificent 7 CVCs pursue alpha and EPS growth from biotech. Public markets reopen, with biopharma IPOs rebounding to 30 listings from just 8 in 2025. While M&A above \$1 billion remains active, at least one transformational "mega-mega" transaction exceeding \$50 billion is fuelled by low interest rates supporting debt-financed M&A, echoing the landmark deals of 2020–2021.

The US market stabilizes, Europe operates with greater cohesion and a new boldness, and the UK surges on clearer reimbursement and policy visibility following VPAG and the Life Sciences Sector Plan. As technology continues to flatten the world, new innovation ecosystems emerge, with biotech unicorn mega-deal financings breaking out in both India and Africa. China-originated innovation remains a core source of global pipelines, while scaled tech-bio platforms materially compress development timelines and shorten time to exit.



Med Device

Blurred Lines Early, Large Scale Late

2025 MedTech financing in Europe reached a three-year high despite ongoing volatility from tariffs and broader policy shifts. However, the year was defined by selectivity, with growth driven by capital concentration into later stage, high conviction rounds rather than an increase in deal activity.

Looking ahead these dynamics are likely to persist. Capital is expected to remain selective, with limited re-engagement in early technical risk, challenging long term pipeline formation in Europe.

Surgical robotics and NIM are key segments to watch, with continued emphasis on solutions that shorten procedure times, reduce costs and move care out of hospital settings.

AI will continue to become more deeply embedded across MedTech devices, operating models and commercial strategies, supporting faster adoption, measurable outcomes and competitive edge. However, demonstrating clear health economic impact will remain critical.

With public markets still selective, M&A will continue to dominate as the primary exit route, with increased deal activity and greater competition for the highest quality assets.



HealthTech

Early Stage: New Series A Market; Late Stage: In Search of Exit, Where's the Rollup?

Healthtech's years long "breakeven" and "EBITDA positive" mantras have seemingly created a **new early ecosystem for healthtech investing**. Founders are bootstrapping to significant ARR and looking for that round that assures 18-24 months runway, or provides enough cash cushion, on top of an already multiple-driven business, to potentially avoid future dilution. This **new Series A** profile for UK and Europe may create additional opportunities for growth investors (and potential mega dealing).

For the later stage healthtech market, we wonder where will these robust healthtech profiles exit? Will the London Stock Exchange or EuroNext surge with cash rich healthtech companies, or is it more likely that the private equity trend we've seen in the United States, begins to take shape across the region for a new multilingual, multicultural rollup strategy across various EU member states? With 2026 beginning with some **notable healthtech mega deals** (e.g. Oviva), we do think the UK's H2 2026 (with new venture capital trust rules in-play) may create some positively frothy activity.

Finally, while investors take note of deeptech (and defense) opportunities, we do believe history has shown that healthcare follows in the wake of such spending.



© 2026 HSBC Innovation Bank Limited. All rights reserved. HSBC Innovation Bank Limited (trading as HSBC Innovation Banking) is registered in England and Wales at Alphabeta, 14-18 Finsbury Square, London EC2A 1BR, UK (Company Number 12546585). HSBC Innovation Bank Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority (Firm Reference Number 543146). HSBC Innovation Bank Limited is part of the HSBC Group. HSBC Innovation Bank Limited is committed to making its website and related documents accessible to everyone. Learn more on www.hsbcinnovationbanking.com/accessibility